PCM
UNCY icon

Prelude Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Prelude Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$80.5K Buy
+12,231
New +$80.2K 0.01% 1082

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prelude Capital Management's UNCY Position: Q1 2026 in Review

Prelude Capital Management opened a new position in Unicycive Therapeutics (UNCY) in Q1 2026: 12,231 shares worth $80.5K. The stake represents 0.01% of the portfolio and ranks #1082 among its holdings.

51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Prelude Capital Management held 12,231 shares of Unicycive Therapeutics worth $80.5K as of Q1 2026.
  • Unicycive Therapeutics was a new Prelude Capital Management position in Q1 2026.
  • Unicycive Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1082 holding.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.